The Value of Positron Emission Tomography for Confirmation of Alzheimer's Disease in the Era of Amyloid-Targeting Therapies.

Objectives: Amyloid-targeting therapies (ATTs) for Alzheimer's disease (AD), such as lecanemab, target and reduce brain β-amyloid plaques. To initiate therapy accurately, confirming the presence of brain β-amyloid plaques is necessary. This research investigated the added value and cost-effectiveness of F-flutemetamol positron emission tomography (PET) in the United States (US).